TICKERNERD
Menu
AKTSHealthcare · Biotechnology

AKTS Stock Forecast: Aktis Oncology, Inc. Price Predictions for 2026-2027

Last close, 14 Oct 2026
$16
−0.90% on the day

The 10 Wall Street analysts covering Aktis Oncology, Inc. hold a median 12-month price target of $35 — +112.2% from the last close. Ticker Nerd's systematic factor model, run across ~4,600 US stocks, ranks it 1 of 100 as at 14 Oct 2026 — in the weakest quartile. The Street sees upside; the factor read is a caution. That gap is the story on this page.

Market cap
$917.2M
Ticker Nerd rank
1 / 100
Median analyst target
$35
Analysts covering
10
Revenue$3.4M+133.9% y/y
Operating income−$28.9M
Net income−$24.1M
Free cash flow−$21.8M
Quarterly, 8 quarters to 30 June 2026 · latest quarter's figure shown
Total return, dividends reinvested
1W
−8.4%
1M
−28.8%
From high
−48.8%
From low
+8.6%
$15
$32
Range since 9 Jan 2026, adjusted closes · the dot is the last close
Ticker Nerd rank

AKTS stock analysis: one number for the whole business

Consensus tells you what everyone already believes. The model scores Aktis Oncology, Inc. on its factor families — the same systematic rank behind the Ticker Nerd portfolio.

Where the model ranks itAs at 14 Oct 2026
1 / 100

Percentile across ~4,600 US stocks on Ticker Nerd’s systematic factor model. Higher is better. How the model is built and tested

Size
45
Revisions
39
Value
10
Issuance
9
Accruals
8
Growth
8
Momentum
4
Volatility
3
Quality
3

Size (45): Smaller than most of the companies we track.

Quality (3): Profits are thin or unreliable for the size of the business, or they are not turning into cash.

Built and run by Aslam Ghouse, an ex-Goldman Sachs quant trader with fourteen years in markets.

Wall Street

AKTS stock forecast 2026-2027: analyst price targets & predictions

The bullish and bearish analyst opinions on AKTS, reported as data — targets and ratings, the market's view beside the model's.

Share price and the analyst range, since 9 Jan 2026Adjusted close, US dollars
$15$20$25$30$35$40Apr 26Jul 26Oct 26AKTSHigh $40Median $35Low $32

Price targets and ratings are third-party analyst estimates, reported here as data. They are not Ticker Nerd forecasts, and they are frequently wrong.

Data provided by Twelve Data

What Wall Street says10 analysts
10 Buy0 Hold0 Sell
Low $32Median $35High $40

The green dot is the last close — the median target sits +112.2% from it.

Recent analyst actionsNewest first
DateFirmActionRatingTarget
2 Oct 2026WedbushReiteratesOutperform$35
9 Sept 2026OppenheimerInitiatesOutperform—
9 Sept 2026OppenheimerInitiatesOutperform$40
19 Aug 2026BMO CapitalInitiatesOutperform$37
19 Aug 2026BMO CapitalInitiatesOutperform—
19 Aug 2026WedbushInitiatesOutperform—
19 Aug 2026WedbushInitiatesOutperform$35
14 July 2026JP MorganMaintainsOverweight—
14 July 2026JP MorganMaintainsOverweight$30 → $33
16 June 2026Raymond JamesInitiatesStrong Buy—
16 June 2026Raymond JamesInitiatesStrong Buy$40
2 June 2026HC Wainwright & Co.MaintainsBuy—
29 Apr 2026William BlairInitiatesOutperform—
31 Mar 2026HC Wainwright & Co.MaintainsBuy—
9 Mar 2026HC Wainwright & Co.InitiatesBuy—
3 Feb 2026JP MorganInitiatesOverweight—
3 Feb 2026Leerink PartnersInitiatesOutperform—
4 Jan 2024Piper SandlerDowngradeNeutral—
7 Sept 2023B. Riley SecuritiesDowngradeNeutral—
7 Sept 2023OppenheimerMaintainsOutperform—

Price targets and ratings are third-party analyst estimates, reported here as data. They are not Ticker Nerd forecasts, and they are frequently wrong.

Market Radar

This page is one stock. Monday covers all of them.

Computed off the Friday close and sent before the US open.

Market Radar reports the week’s largest rank changes across roughly 4,600 US stocks, the factor behind each one, and where the market went. AKTS appears on the weeks it earns a place.

Free, every Monday. Unsubscribe any time.

Performance

AKTS vs the S&P 500

Both lines are total return — dividends reinvested — so the comparison is honest on both sides.

AKTS vs S&P 500, last 12 monthsTotal return, rebased to 100
708090100110120130Apr 26Jul 26Oct 26AKTSS&P 500

Download this chart as an image — free to reuse; link this page as the source.

Data provided by Twelve Data

Estimates

AKTS analyst estimate revisions

Not the forecast itself — the direction analysts are revising it. Revision direction is one of the model's factor families.

Which way the estimates are movingNext fiscal year
Analysts raising
1
Analysts cutting
3
Fundamentals

Aktis Oncology, Inc. (AKTS) financial data

A margin means little on its own. Each bar marks where the figure sits across the whole US universe we score.

Valuation
Trailing P/E
−13.6×

Cheaper than 95% of US stocks

Price / sales
91.2×

Cheaper than 4% of US stocks

Price / book
1.9×

Cheaper than 45% of US stocks

EV / EBITDA
−4.9×

Cheaper than 80% of US stocks

Growth & margins
Revenue growth (YoY)
111.4%

Higher than 93% of US stocks

Earnings growth (YoY)
133.9%

Higher than 87% of US stocks

Gross margin
—
Operating margin
−854.0%

Higher than 6% of US stocks

Net margin
0.0%

Higher than 30% of US stocks

Returns & dividend
Return on equity
43.6%

Higher than 92% of US stocks

Return on assets
−24.1%

Higher than 17% of US stocks

Dividend yield
0.0%

Higher than 1% of US dividend payers

Bars mark the percentile across the ~4,600 US stocks Ticker Nerd covers, among those reporting the figure.

Key statistics

Aktis Oncology, Inc. (AKTS) statistics: revenue, profit & scale

The headline figures, each with its date. Every row carries its own link — cite it straight from here.

  • Aktis Oncology, Inc. has a market value of $917.2M and an enterprise value of $411.1M.

  • Revenue in the twelve months to 30 June 2026: $10.1M. The latest quarter grew 111.4% year on year.

  • Net income over the same four quarters: −$73.1M, a −727.0% net margin.

  • Free cash flow in the twelve months to 30 June 2026: −$84.6M.

  • Shares outstanding: 55.3M.

  • Trailing P/E: −13.6×; forward P/E: −7.7× — the forward figure prices analyst consensus estimates, not reported earnings.

  • Forward dividend yield: 0.00%, paying out 0% of earnings.

  • Aktis Oncology, Inc. employs 79 people — $127K of revenue per employee.

Statement figures: company filings via Twelve Data, four quarters to 30 June 2026 · market figures as at 15 Oct 2026

Data provided by Twelve Data

Peers

AKTS vs competitors

The nearest names by industry and size, scored by the same model — like for like.

Its peer group, ranked by the same modelBiotechnology
CompanyMarket capTKN rank
AKTSAktis Oncology, Inc.$917.2M
1
MNKDMannKind Corp.$930.5M
34
SVRASavara, Inc.$936.1M
35
LTGOLatigo Biotherapeutics, Inc.$885.3M
1
SPTXSeaport Therapeutics, Inc.$884.5M
2
MGTXMeiraGTx Holdings Plc$871.0M
82
SLBTSL Science Holding Ltd.$869.2M
0

Look up any of the roughly 4,600 stocks we score.

The rank is the raw material. Whether the rules would actually own Aktis Oncology, Inc. — and when they’d sell — is the membership. See the Ticker Nerd 20 →

News

Latest AKTS news & analysis

Aktis Oncology: Padcev Is Building The Market It Wants

Seeking Alpha · 14 Oct 2026positive

Seeking Alpha describes Aktis Oncology as trading below its IPO price despite substantial cash reserves and two clinical programs, citing a runway into 2029 and a partnership with Eli Lilly. It also highlights AKY-1189 and AKY-2519, including Fast Track status and early human dosimetry data.

Why it matters — The article emphasizes Aktis's funding position, partnership, and clinical progress as factors relevant to investors following AKTS.

Aktis Oncology Initiates Second Phase 1b Clinical Trial for AKY-2519, a Miniprotein Radioconjugate Targeting B7-H3

GlobeNewsWire · 1 Oct 2026positive

Aktis Oncology announced the initiation of the Phase 1b BActinium-2 clinical trial for AKY-2519, a miniprotein radioconjugate targeting B7-H3, in patients with non-small cell lung cancer and other B7-H3 expressing solid tumors. Enrollment is ongoing in the previously initiated Phase 1b BActinium-1 trial in metastatic castration-resistant prostate cancer, with preliminary data expected in 2027.

Why it matters — This trial expansion advances AKY-2519's development across multiple B7-H3 expressing tumor types, broadening the company's clinical pipeline in targeted radiopharmaceuticals.

Bank of America Sees Bargains in These 16 Knocked-Down AI Stocks

Investopedia · 14 Aug 2026neutral

Bank of America analysts said that a pullback in the AI trade has created opportunities for bargain-hunting investors, and they identified 16 knocked-down AI stocks as potential bargains. The excerpt does not name specific companies beyond the general AI-stock list.

Why it matters — The item does not mention Aktis Oncology or its business, so its direct relevance to AKTS watchers is limited to whether AKTS appears among the named stocks.

FAQ

Frequently asked questions about AKTS stock

What is the AKTS stock price forecast for 2026-2027?

The 10 Wall Street analysts covering Aktis Oncology, Inc. have a median 12-month price target of $35, with estimates ranging from $32 to $40. These are third-party analyst estimates, not Ticker Nerd forecasts, and they are frequently wrong.

Is AKTS stock a buy right now?

Of the 10 analysts covering Aktis Oncology, Inc., 10 rate it a Buy, 0 a Hold and 0 a Sell. Ticker Nerd's systematic factor model ranks Aktis Oncology, Inc. 1 out of 100 across roughly 4,600 US stocks as at 14 Oct 2026. None of this is personal advice — it does not consider your circumstances.

How does Ticker Nerd's model rank AKTS?

As at 14 Oct 2026, Aktis Oncology, Inc. ranks 1 out of 100 on Ticker Nerd's systematic factor model — a percentile across roughly 4,600 US stocks, built from its factor families. Its strongest factor family is Size (45 of 100).

Will AKTS stock go up?

No one can know that. What the data says: the median 12-month target from 10 analysts implies +112.2% from the last close, and Ticker Nerd's factor model ranks Aktis Oncology, Inc. 1 out of 100 as at 14 Oct 2026. Analyst targets are third-party estimates and frequently wrong; none of this is personal advice.

What is the AKTS stock forecast for 2030?

No analyst covering Aktis Oncology, Inc. publishes a 2030 price target — Wall Street targets run 12 to 18 months out. Sites quoting a 2030 price for AKTS are extrapolating price history, which says nothing about the business. The furthest attributed numbers are the current analyst targets: $32 to $40 over the next 12 months.

What does Aktis Oncology, Inc. do?

Akoustis Technologies Inc. is a technology company specializing in the design, development, manufacture, and sale of radio frequency (RF) filter products for the wireless industry across the Americas, Asia, Europe, and other international markets.

What is the latest news on AKTS?

The most recent item we track (Seeking Alpha, 14 Oct 2026): "Aktis Oncology: Padcev Is Building The Market It Wants". Seeking Alpha describes Aktis Oncology as trading below its IPO price despite substantial cash reserves and two clinical programs, citing a runway into 2029 and a partnership with Eli Lilly. It also highlights AKY-1189 and AKY-2519, including Fast Track status and early human dosimetry data.

Company

About Aktis Oncology, Inc.

Akoustis Technologies Inc. is a technology company specializing in the design, development, manufacture, and sale of radio frequency (RF) filter products for the wireless industry across the Americas, Asia, Europe, and other international markets. It leverages proprietary bulk acoustic wave (BAW) technology, including its microelectromechanical system (MEMS)-based XBAW manufacturing process, to produce high-performance filters optimized for high power, high frequency, and wide bandwidth applications. The company operates through two primary segments: Fabrication Services, which offers engineering review and backend packaging services, and RF Filters, focused on amplifier and filter product sales. Its solutions serve critical applications in smartphones, tablets, cellular infrastructure equipment, Wi-Fi customer premise equipment, and military and defense systems. Akoustis Technologies Inc. also provides complementary products such as surface acoustic wave resonators, crystal resonators and oscillators, ceramic products, and back-end semiconductor supply chain services. Headquartered in Huntersville, North Carolina, the company plays a specialized role in advancing RF front-end modules for next-generation wireless connectivity.

CEO Dr. Matthew Roden Ph.D. · 79 employees · United States · https://www.aktisoncology.com